Somni bene Institut fuer medizinische Forschung und Schlafmedizin Schwerin GmbH
- Address
- lock Available on a paid plan
Sleep Medicine and Circadian Disorders
At Somni bene Institut fuer medizinische Forschung und Schlafmedizin Schwerin GmbH, a major focus is on sleep medicine and circadian rhythm disorders. Research here includes insomnia disorder, delayed sleep-wake phase disorder, narcolepsy with cataplexy, and sleep problems linked to nocturia and menopause, with studies aimed at improving symptom control and daily functioning.
- Evaluating new treatments for insomnia and related sleep disruption
- Studying therapies for circadian rhythm misalignment and sleep timing problems
- Assessing options for narcolepsy and excessive daytime sleepiness
This work is centered on finding safer and more effective ways to improve sleep quality, restore regular sleep patterns, and reduce the impact of sleep-related conditions on everyday life.
Pain, Neurology, and Musculoskeletal Research
The site also conducts trials in nervous system diseases and musculoskeletal diseases, especially for people living with diabetic peripheral neuropathic pain, chronic low back pain, and other persistent pain conditions. These studies are designed to test new approaches that may better relieve pain when standard treatments are not enough.
- Testing treatments for diabetic neuropathic pain
- Exploring options for chronic non-specific low back pain
- Evaluating pain relief strategies for difficult-to-treat chronic pain
The research reflects a strong interest in improving pain management, especially for patients whose symptoms remain uncontrolled despite usual care.
Psychiatry and Mood Disorders
A substantial part of the clinical research portfolio addresses psychiatry and psychology, particularly major depressive disorder and depression with anxious distress. Trials in this area are focused on assessing new antidepressant strategies and adjunctive treatments to support people who do not respond adequately to existing therapy.
- Investigating treatments for major depressive disorder
- Studying add-on approaches for inadequate antidepressant response
- Examining safety and symptom improvement in depression with anxious distress
These studies aim to improve mood symptoms, expand treatment choices, and offer more personalized options for adults living with depression.
Metabolic Health and Obesity-Related Conditions
Research at the Schwerin site also covers nutritional and metabolic diseases, including obesity and overweight. Some trials connect metabolic health with breathing and sleep outcomes, reflecting the close relationship between body weight, sleep quality, and overall health.
- Evaluating therapies for obesity and overweight
- Studying the impact of weight-related treatment on obstructive sleep apnea
- Exploring links between metabolic health and sleep-related disease burden
The goal is to identify treatments that may support healthier weight management while also improving related symptoms such as breathing disturbances during sleep.
Women’s Health and Sleep-Related Symptoms
The site includes research in female urogenital diseases and pregnancy complications, with attention to symptoms that affect women’s wellbeing, such as sleep disturbances associated with menopause. This area links women’s health to restorative sleep and quality of life.
- Studying sleep disruption linked to menopause
- Assessing symptom relief in women with hormone-related sleep problems
- Exploring new approaches to improve night-time rest and daytime comfort
These trials are intended to better understand how women’s health conditions affect sleep and to evaluate therapies that may ease these burdens.
Cross-Disciplinary Symptom Management
Several studies at Somni bene Institut fuer medizinische Forschung und Schlafmedizin Schwerin GmbH bridge multiple therapeutic areas, combining sleep medicine, pain research, psychiatry, and metabolic health. This reflects a broader effort to address symptoms that often overlap across conditions, such as fatigue, poor sleep, pain, and reduced wellbeing.
- Testing therapies that target more than one symptom domain
- Evaluating treatment effectiveness in complex, overlapping conditions
- Improving quality of life through better symptom control
The research landscape is broad but connected, with a clear emphasis on practical treatments that may help patients manage chronic conditions more effectively.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 therapeutic areas and 15 of 20 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 4 by active trials.
- 1Alkermes Inc.2active
lock +3 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Alkermes Inc.2trials
lock +4 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Somni bene Institut fuer medizinische Forschung und Schlafmedizin Schwerin GmbH
lock Showing 1 of 18 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A multi-center, double-blind, randomized, placebo-controlled, 2-way cross-over post approval study to investigate the efficacy of daridorexant in subjects with insomnia and comorbid nocturia | Idorsia Pharmaceuticals Ltd. | Phase III | Not Recruiting | Mar 2023 | Apr 2024 |
IMP list
lock Showing 1 of 20 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Alks 2680 | 2 | Unknown | — | — |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.
